Search This Blog

Wednesday, January 2, 2019

Stryker upgraded to Outperform from In Line at Evercore ISI


https://thefly.com/landingPageNews.php?id=284232

Novartis downgraded to Underweight from Neutral at JPMorgan


JPMorgan analyst Richard Vosser downgraded Novartis to Underweight with a price target of CHF 89. The analyst has concerns over the company’s pipeline and believes the shares are close to fair value.

Bayer downgraded to Neutral from Overweight at JPMorgan


Bayer downgraded to Neutral from Overweight at JPMorgan. JPMorgan analyst Richard downgraded Bayer to Neutral and lowered his price target for the shares to EUR 70 from EUR 100. The analyst believes 2019 will be another “messy year” for the company.

Lundbeck downgraded to Underweight from Neutral at JPMorgan


JPMorgan analyst Richard Vosser downgraded Lundbeck to Underweight and lowered his price target for the shares to DKK 275 from DKK 300. The analyst believes the company’s pipeline represents downside risk.

JPMorgan adds Novo Nordisk to Analyst Focus List, removes Roche


JPMorgan analyst Richard Vosser added Novo Nordisk (NVO) to his firm’s European Analyst Focus List while removing Roche (RHHBY).

Significant synergies seen in Omega, MedEquities Realty Trust deal

Highlights include: Anticipated annual FFO, AFFO and FAD accretion of approximately 5c per Omega share. Operator diversification will increase with 9 new operators. Property type diversification will increase non-skilled nursing assets modestly by $296M, including $75M invested in a hospital facility leased to a subsidiary of Baylor, Scott & White Health. Significant synergies expected. Omega will acquire the fee simple interest in 34 facilities operated by 11 operators in 7 states. Omega will acquire approximately $34M in mortgage loans.

Spectrum announces full enrollment of Poziotinib EGFR cohort in ZENITH20 trial


Spectrum Pharmaceuticals announced full enrollment of cohort 1 for previously treated Non-Small Cell Lung Cancer, or NSCLC, patients with EGFR exon 20 insertion mutations with sites across the U.S., Europe, and Canada. The EGFR previously treated cohort is part of the ZENITH20 trial – an open-label, multi-center, global Phase 2 trial evaluating NSCLC patients with EGFR or HER2 exon 20 insertion mutations. Results from this cohort are expected by the second half of 2019.